Skip to contentS
Supernus Pharmaceuticals, Inc.
S
SUPNSupernus Pharmaceuticals, Inc. Q1 2014 · 10-Q
Revenue$9.08M$9.08M+6,077.6% vs Q1 2013 Net Income-$15.54M-$15.54MN/M vs Q1 2013 EPS Diluted-$0.38-$0.38N/M vs Q1 2013 Operating Income-$13,422,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Supernus Pharmaceuticals, Inc. · CIK 1356576 · Engraved from SEC EDGAR
Free Cash Flowderived-$19,367,000N/M Margins · derivedOperating margin-147.8%+12034.5 pt vs Q1 2013
Net margin-171.2%+12355.4 pt vs Q1 2013
ended Mar 31, 2014 · filed May 13, 2014 · 43 d after period end